Erfaring med topikale NSAID’ er efter markedsføringen viser, at risikoen for potentielt synstruende hornhindebivirkninger kan øges hos patienter, der har gennemgået komplicerede øjenoperationer, haft hornhinde- denervering, defekter i hornhindens epitel, diabetes mellitus, okulære overfladelidelser (f. eks. tørre øjne), reumatoid arthritis eller gennemgået gentagne øjenoperationer inden for en kort periode.
Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e. g., dry eye syndrome), rheumatoid arthritis or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse reactions which may become sight threatening.